Business Context and Reporting Period
This Form 8-K Current Report was filed by Verrica Pharmaceuticals Inc. on December 4, 2024, with the earliest event reported on the same date. The filing primarily addresses the appointment of a new executive officer and amendments to the company's equity incentive plan.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes and Executive Appointment
The Board of Directors appointed David Zawitz as Chief Operating Officer and Principal Operating Officer, effective December 9, 2024. Mr. Zawitz brings experience from PBM Capital Group, LLC, CarMax, Inc., and private legal practice. He holds a CFA charter and a J.D. from the University of Virginia.
- Base Salary: $250,000 annually.
- Target Bonus: 40% of annual base salary.
- Employment Status: At-will employment.
Equity Compensation and Plan Amendments
In connection with the appointment, the Compensation Committee approved a stock option grant and an amendment to the 2024 Inducement Plan.
Stock Option Grant (Zawitz Option)
- Shares Granted: 950,000 shares of common stock.
- Exercise Price: Closing price of common stock on the Grant Date (December 4, 2024).
- Vesting Schedule: 1/8th vests six months after the Effective Date; the remainder vests monthly (1/48th per month) thereafter.
- Change in Control: Full acceleration of unvested shares if terminated without Cause or resigns for Good Reason within 12 months of a Change in Control.
2024 Inducement Plan Amendment
- Share Reserve Increase: Increased from 2,000,000 to 4,500,000 shares.
- Remaining Availability: 1,550,000 shares available for future awards after the Zawitz grant.
- Approval: Adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4).
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the company's operational outlook or financial strategy. The document is strictly a disclosure of the executive appointment and related contractual terms.
Key Facts for Investor Verification
- Verify the closing stock price on December 4, 2024, to determine the exercise price of the 950,000 options granted to Mr. Zawitz.
- Confirm the total number of shares outstanding to assess the dilution impact of the 2.5 million share increase in the Inducement Plan reserve.
- Review the full text of the Offer Letter (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Monitor future filings for the company's next financial report to assess the impact of the new COO on operational strategy.